The global cannula market size was valued at USD 204.22 million in 2025 and is projected to grow from USD 219.43 million in 2026 to USD 389.90 million by 2034, registering a CAGR of 7.45% during the forecast period from 2026 to 2034. North America dominated the cannula market with a market share of 38.5% in 2025.
A cannula is a thin, hollow medical tube designed to provide access to blood vessels, body cavities, or tissues for the administration or removal of fluids, medications, gases, or biological materials. Cannulas are commonly used for intravenous therapy, oxygen delivery, blood collection, drainage, and surgical procedures. They are available in different sizes, shapes, and materials depending on their intended clinical application.
Download a Free Sample To learn more about this report,
Development of Safety Cannulas With Advanced Needle Protection
The need to reduce accidental needlestick injuries and blood exposure is encouraging healthcare providers to adopt cannulas with integrated needle-shielding mechanisms. This transition is improving user safety by automatically covering or retracting the needle after vascular access while also supporting more controlled insertion procedures. For example, BD’s Venflon Pro Safety IV Cannula uses a passive safety system that fully shields the needle tip as it is withdrawn, helping protect healthcare workers from needlestick injuries.
Adoption of Microcannulas for Minimally Invasive Aesthetic Procedures
The demand for less traumatic techniques in dermal filler procedures is encouraging practitioners to use flexible, blunt-tipped microcannulas for facial and soft-tissue applications. This transition can reduce tissue trauma and improve patient comfort while allowing fillers to be distributed through a single entry point in selected procedures. For example, a clinical study involving 95 patients reported lower pain and less bruising with blunt-tip microcannulas than with hypodermic needles during filler injections.
Fluid Delivery and Disposable Clinical Use Drive Market
The need for reliable fluid and medication administration creates requirements for cannulas that provide vascular access during clinical treatment. WHO identifies intravenous administration of drugs and fluids among the major uses of injection procedures and estimates that at least 16 billion injections are administered globally each year. For example, a peripheral intravenous cannula can provide access for fluids, antibiotics, or other medicines during hospital treatment. This routine clinical requirement supports consistent procurement of cannulas and encourages suppliers to provide devices suited to different patient and treatment needs.
The need for infection-controlled clinical procedures creates requirements for sterile, single-use cannulas across healthcare facilities. WHO guidance recommends using a new, sealed needle, syringe, or intravenous cannula for each patient injection and states that injection devices should not be reused between patients. For example, hospitals can use individually packaged sterile IV cannulas during emergency care, surgery, and routine infusion procedures. This infection-prevention requirement supports recurring replacement volumes and creates continued supply requirements for disposable cannula manufacturers.
Skilled Workforce and Infection Risks Restrain Market Expansion
Shortage of skilled healthcare professionals can limit the safe insertion, management, and removal of cannulas during clinical procedures. WHO projects a global health workforce shortage of 11 million workers by 2030, while CDC guidance recommends that only trained and competent personnel perform intravascular catheter insertion and maintenance. This workforce constraint can reduce effective cannula utilization and slow market adoption.
Product-related infection risks can arise from improper cannula insertion, handling, maintenance, or inadequate aseptic practices. CDC guidance emphasizes hand hygiene, aseptic technique, appropriate catheter care, and trained personnel to reduce intravascular catheter-related infections. These infection-control requirements can increase procedural complexity and healthcare costs, limiting the adoption of cannula products.
Antimicrobial Cannula Technologies and Strategic Medical Device Partnerships Offers Growth Opportunities
Cannula manufacturers, medical-device companies, and biomaterial suppliers can develop antimicrobial and antithrombogenic surfaces that help reduce microbial colonization and catheter-related complications. Teleflex reports that several of its vascular-access catheters use antimicrobial and antithrombogenic protection technologies, creating revenue through differentiated cannula products and premium vascular-access solutions.
Cannula manufacturers, pharmaceutical companies, and Medtech/oem companies can collaborate on customized delivery components and integrated medical-device systems. BD provides OEM contract manufacturing and customized kits for medtech companies, including injection products and vascular-access devices, creating revenue through long-term supply agreements and co-developed products.
Product Quality Requirements and Manufacturing Costs Hinders Growth
Cannulas must maintain consistent dimensions, flexibility, flow characteristics, connection integrity, and mechanical performance across production batches. ISO 7864 specifies requirements and test methods for sterile, single-use hypodermic needles, including dimensions, cleanliness, freedom from defects, and mechanical strength. Meeting these requirements increases inspection, testing, and process-control needs for manufacturers, while quality deviations can lead to rejected batches and higher production costs.
Producing precision cannulas at large volumes requires specialized molding, extrusion, forming, assembly, and inspection equipment. The U.S. Food and Drug Administration's guidance on medical-device manufacturing emphasizes process validation where results cannot be fully verified through subsequent inspection and testing, requiring manufacturers to demonstrate that processes consistently produce conforming products. These validation and production requirements can increase capital and operating expenditure, particularly for smaller manufacturers, limiting capacity expansion.
The intravenous cannula segment accounted for a share of 54.6% in 2025, owing to its widespread use for administering medications, fluids, and nutrients directly into the bloodstream across hospitals and other healthcare settings. the increasing number of hospitalizations, growing demand for intravenous therapies, and broad adoption of intravenous access procedures further strengthen the segment’s dominant position in the cannula market.
The peripheral cannula segment is expected to grow at a CAGR of 7.91% during the forecast period, driven by increasing use of peripheral intravenous access, growing demand for minimally invasive drug and fluid administration, and rising adoption across hospitals, clinics, and emergency care settings. the central line cannula segment supports long-term and specialized vascular access, while the draining cannula segment is used for fluid drainage procedures. the nasal cannula segment supports oxygen delivery for patients requiring supplemental oxygen, while the others segment includes additional cannula types used across specialized medical applications.
Request Customizationto receive a tailored report.
The oxygen delivery segment accounted for a 34.9% share in 2025 and is expected to grow at a CAGR of 7.86% during the forecast period 2026-2034, driven by increasing demand for supplemental oxygen, growing prevalence of respiratory conditions, and rising use of nasal cannulas in hospitals and home-care settings. the increasing need for non-invasive oxygen therapy and expanding respiratory care services further strengthens the segment’s dominant position in the cannula market.
The anaesthesia and surgery segment supports controlled delivery of gases and medications during surgical procedures, while the blood sampling segment enables efficient collection of blood specimens for diagnostic testing. the administration of medicine segment contributes through controlled delivery of intravenous and other medications across hospitals and clinical settings.
The 20G segment accounted for a share of 29.4% in 2025 due to its widespread use for intravenous access, medication administration, and fluid delivery across hospitals and clinical settings. the balance between flow rate, patient comfort, and suitability for a broad range of medical procedures further strengthens the segment’s dominant position in the cannula market.
The 22G segment is expected to grow at a CAGR of 7.96% during the forecast period, fueled by increasing use in patients requiring smaller-gauge vascular access, growing demand for minimally invasive procedures, and rising adoption in pediatric, elderly, and other patients requiring delicate intravenous access. the 18G segment supports procedures requiring higher flow rates, while the 14G segment is used for rapid fluid and blood administration in critical care and emergency settings. the others segment includes additional cannula sizes used for specialized clinical applications.
The plastic segment accounted for a share of 62.8% in 2025, supported by its widespread use in disposable cannulas, flexibility, lightweight properties, and suitability for various medical procedures. the increasing preference for single-use medical devices, growing focus on infection prevention, and broad adoption of plastic cannulas across healthcare settings further strengthen the segment’s dominant position in the cannula market.
The silicon segment is expected to grow at a CAGR of 7.52% during the forecast period, propelled by increasing demand for flexible and biocompatible cannula materials, growing use in specialized medical applications, and rising preference for materials that provide patient comfort during prolonged procedures. the stainless steel segment supports applications requiring rigidity, durability, and precise insertion, while the silicon segment contributes through its flexibility and biocompatibility.
The hospitals and clinics segment accounted for a share of 68.5% in 2025, owing to the widespread use of cannulas for medication administration, fluid delivery, oxygen therapy, blood sampling, and surgical procedures across healthcare facilities. the availability of specialized medical infrastructure, high patient volumes, and broad adoption of cannula-based procedures further strengthen the segment’s dominant position in the cannula market.
The ambulatory surgical centres segment is expected to grow at a CAGR of 8.12% during the forecast period, driven by increasing adoption of outpatient procedures, growing preference for minimally invasive treatments, and rising demand for efficient and cost-effective surgical care. the others segment includes additional healthcare settings and specialized facilities that use cannulas for various medical and therapeutic applications.
Speak to an Analystto discuss market opportunities.
The North America cannula market accounted for the largest regional share of 38.5% in 2025, driven by advanced healthcare infrastructure, increasing adoption of minimally invasive procedures, and rising demand for specialized medical devices. The U.S. cannula market is supported by continued regulatory clearance of cannula technologies for cardiovascular and vascular procedures. The FDA classified cardiopulmonary bypass vascular catheters, cannulae, and tubing as class II medical devices and recognized standards covering cannulae for extracorporeal circulation. In 2025, the FDA also cleared medtronic’s MC2 two-stage and MC2X three-stage venous cannulae for cardiopulmonary bypass applications, demonstrating continued development and availability of specialized cannula technologies in the U.S. market.
The Canada cannula market is supported by established vascular-access practices and medical-device regulation. Health Canada maintains regulatory requirements for medical devices, while Canadian clinical guidance emphasizes safe vascular access and appropriate selection and use of peripheral and central cannulation devices, supporting continued demand for cannula technologies across hospitals and critical-care settings.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific cannula market is expected to grow at a CAGR of 8.96%, showcasing the fastest-growing regional market, driven by expanding healthcare infrastructure, increasing surgical procedures, and growing adoption of minimally invasive medical technologies. In Japan, the Pharmaceuticals and Medical Devices Agency (PMDA) published a 2026 review summary for a medical device classified as a catheter for coronary balloon dilatation angioplasty, with approval dated February 19, 2026. PMDA also maintains specific medical-device classifications for venous cannulae and other catheter-based devices, supporting an established regulatory framework for cannula and catheter products in Japan. In China, the national medical products administration (NMPA) released a revised good manufacturing practice (GMP) for medical devices that will take effect on November 1, 2026. The revised requirements strengthen quality-management systems and risk management across the medical-device lifecycle, supporting quality and regulatory compliance for manufacturers of devices such as cannulas.
In South Korea, the ministry of food and drug safety (MFDS) issued an amended medical-device manufacturing and quality-management standard on July 1, 2026. The updated requirements strengthen manufacturing and quality-management controls for medical devices, providing a relevant regulatory development for manufacturers of cannulas and other sterile medical devices. In India, the central drugs standard control organisation (CDSCO) classifies intravenous cannulae as class B medical devices, describing them as passive devices used for infusion of fluids, drugs, and blood components or for facilitating vascular access. CDSCO also classifies several other cannula types, including arterial, coronary artery, hemodialysis, vena cava, venous, and ventricular cannulae, within its medical-device classification framework.
The Europe cannula market accounted for a regional share of 27.2% in 2025, supported by well-established healthcare systems, increasing demand for advanced medical devices, and growing adoption of minimally invasive treatment procedures. In the U.K. cannula market, NHS supply chain is preparing a new framework for intravenous cannula and associated products, with an estimated value of £140 million excluding VAT for the initial period from april 2027 to march 2029, with an option to extend through march 2031.
In the Germany cannula market, medical devices must undergo a conformity assessment before being placed on the German and European markets, with qualified bodies such as TÜV and DEKRA assessing device safety and performance. This regulatory framework supports the availability and adoption of compliant cannula products across healthcare settings. Meanwhile, the France cannula market is supported by the ministry of health's 2025–2027 roadmap to anticipate and prevent medical-device supply shortages and improve product availability. The framework includes measures to strengthen supply security and industrial sovereignty, supporting the reliable availability of products such as cannulas.
The Middle East and Africa cannula market is expected to grow at a CAGR of 6.74%, supported by improving healthcare infrastructure, increasing access to surgical care, and growing investments in advanced medical technologies. The UAE cannula market is expected to benefit from continued expansion of advanced healthcare infrastructure and surgical services. The country’s growing investment in specialized medical facilities and minimally invasive procedures is expected to support demand for cannulas used in intravenous access, anesthesia, surgery, and other clinical applications.
The Africa cannula market is expected to benefit from efforts to expand access to quality-assured medical devices and strengthen local healthcare manufacturing. In August 2026, health ministers in the WHO African region endorsed the regional strategy on regulation of medical products for 2026–2035, which aims to strengthen medical-device regulation, expand digital regulatory systems, and improve access to quality-assured health products. The strategy is expected to support the availability and adoption of essential medical devices, including cannulas, across African healthcare systems.
The cannula market is moderately fragmented, with medical device manufacturers, surgical instrument companies, healthcare technology providers, specialized cannula manufacturers, and contract medical device producers competing across intravenous, infusion, ophthalmic, cardiovascular, cosmetic, and other medical applications. Established players compete primarily on product quality, safety, precision, biocompatibility, technological innovation, manufacturing capabilities, regulatory compliance, product reliability, customization, and global distribution networks, with leading players such as Medtronic, BD, Edwards Lifesciences Corporation, Boston Scientific Corporation, and Terumo Cardiovascular Systems Corporation estimated to account for approximately 45% of the global market based on their product portfolios, technological capabilities, geographic presence, and competitive positioning.
Emerging and regional players within the cannula market ecosystem compete through cost-effective products, specialized cannula designs, application-specific solutions, flexible manufacturing, customized offerings, localized distribution, rapid product development, and improved ease of use to address diverse clinical requirements and strengthen their market presence. These players also focus on developing application-specific cannula solutions, improving product ergonomics, and expanding specialized medical device offerings to differentiate their products and broaden their market reach.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Medical Oxygen Concentrators Market Size, Share, Growth, 2034
General Surgical Devices Market Size, Share, Growth, Analysis, 2034
Medical Gloves Market Size, Share, Growth, Analysis, Report, 2034
Cervical Pillows Market Size, Share, Growth, Analysis, 2034
Facial Cleansing Devices Market Size, Share, Growth, Analysis, 2034
Dental Implants and Prosthesis Market Size, Share, Trends, Report, 2034
We are featured on:
sales@straitsresearch.com